Albany, NY -- (SBWIRE) -- 01/24/2018 -- Febrile neutropenia is defined as the development of fever with the sign of infection. Febrile neutropenia is one of the most severe complications of cancer chemotherapy and is mainly caused by infectious agents like gram-positive and gram-negative bacteria. This diseased condition significantly reduces white blood cell count of the patients. A blood test is helpful to determine the number of white blood cells and to diagnose febrile neutropenia disease. Additionally, a patient with febrile neutropenia is treated with prophylactic antibiotics to recover from persistent or recurrent fever conditions.

The market of febrile neutropenia is majorly driven by the efforts of key players to develop novel and cost-effective therapeutics. For example, in July 2014, Taiho Pharmaceutical Co., Ltd. filed an application for approval of ZOSYN 2.25 and ZOSYN 4.5 (generic name- tazobactam piperacillin) for the additional indication of febrile neutropenia. This product is a combination of antibacterial ?-lactamase inhibitor and can be used intravenously. Moreover, in April 2014, Amgen, Inc. collaborated with ONS Edge, Inc. to help educate nurses regarding the patients who are at the risk of febrile neutropenia.

Thus, these types of efforts will build a healthy platform to develop the market of febrile neutropenia hence stimulates the market growth. Additionally, a large number of therapeutics under clinical pipelines by key companies will further stimulate the market growth in near future. Positive initiatives by North American and European governments will further drive the market growth of febrile neutropenia. For example, in September 2013, U.S. Food Drug and Administration (U.S. FDA) approved phase III study of Neulasta (pegfilgrastim) by Amgen, Inc. This study demonstrates an increase of white blood cells in patients who are undergoing myelosuppressive chemotherapy.

In addition, in June 2010, Nivestim (TM), a new biosimilar filgrastim by Hospira, Inc. is approved by European Commission. This drug is mainly used for the prevention of febrile neutropenia and offers a cost-effective treatment option for neutropenia. However, lack of specific treatment that enables to treat all the symptoms of this disorder may restrain the growth of this market. In addition, high generic competition among the key players leads to price erosion and ultimately restrains the overall growth of febrile neutropenia market.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2857

The market of febrile neutropenia can be segmented on the basis of:

By Therapeutics Molecule Types
Pegfilgrastim
Vancomycin hydrochloride
Filgrastim biosimilars
Pegfilgrastim biosimilars
Stimuxen
Others

Geographically, North America dominates the global febrile neutropenia market. High degree of therapeutic needs for febrile neutropenia coupled with the presence of a large number of key players like Amgen, Inc., Aequus BioPharma, Inc. and others in the North American market will drive the growth of the market. Europe is considered as the second largest market of febrile neutropenia. A large pool of patients under the diagnosis of this disease coupled with increasing demand for treatment fuels the growth of febrile neutropenia market.

In addition, Asia-Pacific region is considered as an emerging market for febrile neutropenia due to the launch of novel drugs with improved efficacy by key companies. In addition, growing awareness of this disorder among the people will further stimulate the growth of febrile neutropenia market in Asia-Pacific region.

Some of the key players in the febrile neutropenia market include Xenetic Biosciences plc, Richter Gedeon Nyrt., Amgen, Inc., Hospira, Inc., Eli Lilly and Company, USV Limited, Aequus BioPharma, Inc., Taiho Pharmaceutical Co., Ltd., and others.

Pre-Book Full Report @ https://www.transparencymarketresearch.com